Stockscreener 앱 받기
3.055
8.74%
0.195
전일 마감가:
$2.86
열려 있는:
$3.08
하루 거래량:
8,658
Relative Volume:
0.02
시가총액:
$68.33M
수익:
$160.43M
순이익/손실:
$-227.64M
주가수익비율:
-0.0444
EPS:
-68.77
순현금흐름:
$-170.79M
1주 성능:
-0.96%
1개월 성능:
+99.36%
6개월 성능:
-25.06%
1년 성능:
-76.21%
1일 변동 폭
$3.01
$3.095
1주일 범위
$2.70
$3.19
52주 변동 폭
$1.38
$19.69
아제너스 Stock (AGEN) Company Profile
명칭
Agenus Inc
전화
781-674-4410
주소
3 FORBES ROAD, LEXINGTON, MA
AGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.05 | 68.33M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.67 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.38 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.07 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
263.86 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.63 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
아제너스 Stock (AGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 개시 | Robert W. Baird | Outperform |
| 2023-02-28 | 재개 | H.C. Wainwright | Buy |
| 2022-09-28 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-04-22 | 개시 | B. Riley FBR | Buy |
| 2016-10-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 재확인 | Maxim Group | Buy |
| 2016-03-11 | 업그레이드 | Maxim Group | Hold → Buy |
| 2015-12-16 | 개시 | Jefferies | Buy |
| 2015-10-27 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-07-27 | 재확인 | MLV & Co | Buy |
| 2015-06-11 | 개시 | Oppenheimer | Outperform |
| 2015-01-12 | 재확인 | Maxim Group | Buy |
| 2015-01-09 | 재확인 | MLV & Co | Buy |
| 2015-01-09 | 재확인 | Maxim Group | Buy |
| 2014-12-19 | 재확인 | Maxim Group | Buy |
| 2014-05-08 | 재확인 | Maxim Group | Buy |
| 2014-03-14 | 재확인 | MLV & Co | Buy |
| 2013-10-08 | 재확인 | Maxim Group | Buy |
| 2012-01-05 | 개시 | William Blair | Outperform |
| 2011-12-01 | 개시 | Global Hunter Securities | Buy |
모두보기
아제너스 주식(AGEN)의 최신 뉴스
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financ - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AAC - GuruFocus
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 - The Joplin Globe
New Clinical Data: Agenus' BOT/BAL Achieves 72% Disease Control Rate in Treatment-Resistant Liver Cancer - Stock Titan
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Agenus Announces Botensilimab and Balstilimab Presentations at A - GuruFocus
Breakthrough Cancer Drug Data: Agenus to Present 3 New Studies on Botensilimab at ASCO 2025 - Stock Titan
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 - The Joplin Globe
Agenus (AGEN) Price Target Slashed by B. Riley Analyst, Buy Rati - GuruFocus
Agenus (AGEN) Price Target Slashed by B. Riley Analyst, Buy Rating Maintained | AGEN Stock News - GuruFocus
B. Riley Cuts Price Target on Agenus to $8 From $11, Keeps Buy Rating - marketscreener.com
Agenus Inc. (AGEN) to Present Key Cancer Research at AACR Meetin - GuruFocus
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Agenus stock hits 52-week low at $1.44 amid sharp annual decline - Investing.com Australia
Agenus stock hits 52-week low at $1.44 amid sharp annual decline By Investing.com - Investing.com South Africa
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
Agenus Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus stock hits 52-week low at $1.53 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.53 amid sharp annual decline - Investing.com India
Breakthrough Cancer Treatment Data: Agenus BOT/BAL Shows Promise Across Multiple Cancers - Stock Titan
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Agenus stock hits 52-week low at $1.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.64 amid sharp annual decline - Investing.com Australia
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation - Lelezard
93% of Doctors Say Current Colorectal Cancer Treatments Fall Short, New Study Shows - Stock Titan
H.C. Wainwright maintains neutral on Agenus stock post-10-K filing - Investing.com Australia
AGENUS INC SEC 10-K Report - TradingView
Gilead Sciences : Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead - Marketscreener.com
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for Agenus Q1 Earnings - Defense World
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - Defense World
Agenus stock falls after revenue miss - MSN
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL
아제너스 (AGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.70%
3.92%
자본화:
|
볼륨(24시간):